Please contact our Patient and Liaison Services (PALS) Program at 877-272-6226 or email us at pals@pancan.org. We will provide no-cost comprehensive disease information, as well as information on managing pain, diet and nutrition, clinical trials and so much more. Click to learn more.

Research performed by or involving scientists who have received Pancreatic Cancer Action Network research grants are featured among other pancreatic cancer scientists. Click to read.

The Pancreatic Cancer Action Network recognizes the imperative need to advance scientific breakthroughs for this disease through clinical trials. We are here to help you better understand all aspects of clinical trials. Begin by viewing this newly released video.

This bold initiative intensifies efforts to grow our community of scientists, increase annual federal research dollars, enroll more patients in clinical trials and increase national awareness by attracting more volunteers and participants to our events. Take action now. Click to learn how. To watch and share the Vision of Progress 2020 video, click here.

Celgene Corporation has released the data from its phase III study showing that the addition of ABRAXANE to gemcitabine extends overall survival by nearly two months in patients with untreated metastatic pancreatic cancer, compared to patients receiving gemcitabine alone. A 59 percent increase in one-year survival was also reported. Click to learn more.